{
    "medicine_id": "1092b432c4bb7cccb0cd2e2968977cfd99e42856",
    "platform_id": "DB15528",
    "metadata": {
        "name": "Zolgensma",
        "composition": "Onasemnogene abeparvovec",
        "clinical_particulars": {
            "therapeutic_indications": "Onasemnogene abeparvovec is indicated for the treatment of pediatric patients less than 2 years of age neonatal and infant patients with spinal muscular atrophy SMA with bi allelic mutations in the survival motor neuron 1 SMN1 gene L9194",
            "contraindications": {
                "disease": "The LD sub 50 sub and information on overdose have not been evaluated with onasemnogene abeparvovec In mice toxicology studies dose dependent cardiac and hepatic toxicities were observed following intravenous administration Cardiac toxicity was characterized by mononuclear cell inflammation accompanied by edema slight to mild fibrosis and scattered myocardial cell degeneration regeneration as well as atrial thrombosis and dilation Hepatotoxicity was characterized by hepatocellular hypertrophy Kupffer cell activation perinuclear vacuolation and scattered hepatocellular necrosis L9194",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Onasemnogene abeparvovec is a gene therapy that restores the levels of SMN protein in the spinal cord to promote the survival and function of motor neurons Acute serious liver injury and elevated aminotransferases were observed with the treatment of onasemnogene abeparvovec in clinical trials L9194",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB12978",
                        "description": "Onasemnogene abeparvovec may increase the hepatotoxic activities of Pexidartinib"
                    },
                    {
                        "drugbank-id": "DB10317",
                        "description": "The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Onasemnogene abeparvovec"
                    },
                    {
                        "drugbank-id": "DB10318",
                        "description": "The therapeutic efficacy of Varicella Zoster Vaccine Live attenuated can be decreased when used in combination with Onasemnogene abeparvovec"
                    },
                    {
                        "drugbank-id": "DB10343",
                        "description": "The therapeutic efficacy of Bacillus calmette guerin substrain tice live antigen can be decreased when used in combination with Onasemnogene abeparvovec"
                    },
                    {
                        "drugbank-id": "DB10804",
                        "description": "The therapeutic efficacy of Bacillus calmette guerin substrain connaught live antigen can be decreased when used in combination with Onasemnogene abeparvovec"
                    },
                    {
                        "drugbank-id": "DB10805",
                        "description": "The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Onasemnogene abeparvovec"
                    },
                    {
                        "drugbank-id": "DB11003",
                        "description": "The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Onasemnogene abeparvovec"
                    },
                    {
                        "drugbank-id": "DB11050",
                        "description": "The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Onasemnogene abeparvovec"
                    },
                    {
                        "drugbank-id": "DB12386",
                        "description": "The therapeutic efficacy of Bacillus calmette guerin substrain danish 1331 live antigen can be decreased when used in combination with Onasemnogene abeparvovec"
                    },
                    {
                        "drugbank-id": "DB12768",
                        "description": "The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Onasemnogene abeparvovec"
                    },
                    {
                        "drugbank-id": "DB14409",
                        "description": "The therapeutic efficacy of Human adenovirus e serotype 4 strain cl 68578 antigen can be decreased when used in combination with Onasemnogene abeparvovec"
                    },
                    {
                        "drugbank-id": "DB14443",
                        "description": "The therapeutic efficacy of Vibrio cholerae CVD 103 HgR strain live antigen can be decreased when used in combination with Onasemnogene abeparvovec"
                    },
                    {
                        "drugbank-id": "DB14685",
                        "description": "The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Onasemnogene abeparvovec"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}